Fig. 7: Improved antitumor effect of HS201-PDT against MDA-MB-231 tumors in SCID-beige mice.

a Antitumor effect of HS201-PDT and VP-PDT against MDA-MB-231 tumors in vivo. MDA-MB-231 tumor-bearing mice were administered VP or HS201 (25 nmol/mouse) via tail vein. The laser irradiation (690 nm wavelength, 120 J/cm²/4 min) was applied to the tumor area with DLI of 6 and 24 h (red arrows). The data shown are average ± SEM of tumor volumes (n = 8 for each group). Student’s t test was performed for the comparison of two treatments. b Comparison of the tumor weight among treatment groups. At the end of the experiment (day 25 after treatment initiation), mice were euthanized and all tumors were excised and weighed (n = 8 for each group). Welch t test was used for statistical analysis. c Antitumor effect of repetitive HS201-PDT against MDA-MB-231 tumors in vivo. MDA-MB-231 tumor-bearing mice were administered VP or HS201 (25 nmol/mouse) via tail vein. The laser irradiation (690 nm wavelength, 120 J/cm²/4 min) was applied to the tumor area with DLI of 6 and 24 h (red arrows). Initial PDT treatment was performed on days 0 and 1 and repeated on days 6 and 7. As controls, no treatment and single HS201-PDT (treated on days 0 and 1) groups were made. Averages ± SEM of tumor volumes for each group (n = 14 for no treatment group, n = 14 for single HS201-PDT group, n = 15 for repetitive HS201-PDT group) are shown. ANOVA and Tukey’s test were performed for statistical analysis. Red arrows indicate laser exposures. d Survival of MDA-MB-231 tumor-bearing mice treated with single or repeated HS201-PDT (n = 14 for no treatment group, n = 14 for single HS201-PDT group, n = 15 for repetitive HS201-PDT group). Mice were counted as dead when the tumor volume reached humane endpoint according to IACUC approved protocol (>2000 mm³). Survival data was analyzed with the Cox Proportional Regression Model followed by Tukey’s test.